{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T13:08:44Z","timestamp":1702040924635},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1007\/s11938-001-0039-x","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T13:15:14Z","timestamp":1180876514000},"page":"267-273","source":"Crossref","is-referenced-by-count":2,"title":["Refractory inflammatory bowel disease"],"prefix":"10.1007","volume":"4","author":[{"given":"Thomas A.","family":"Judge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"39_CR1","volume-title":"Advanced Therapy of Inflammatory Bowel Disease","author":"A Rogers","year":"2000","unstructured":"Rogers A: Pseudo-intractability of inflammatory bowel disease. In Advanced Therapy of Inflammatory Bowel Disease. Edited by Bayless T, Hanauer S. Hamilton, Canada: BC Decker, Inc; 2000. Concise review of clinical conditions which may confound diagnosis and treatment of refractory colitis."},{"key":"39_CR2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJM197308022890506","volume":"289","author":"B Blackwell","year":"1973","unstructured":"Blackwell B: Drug therapy: patient compliance. N Eng Med 1973, 289:249\u2013252.","journal-title":"N Eng Med"},{"key":"39_CR3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0095-4543(05)70349-3","volume":"23","author":"B Stotland","year":"1996","unstructured":"Stotland B, Lichtenstein G: Newer treatments for inflammatory bowel disease. Prim Care 1996, 23:577\u2013608.","journal-title":"Prim Care"},{"key":"39_CR4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/gut.16.8.579","volume":"16","author":"J Lennard-Jones","year":"1975","unstructured":"Lennard-Jones J, Ritchie J, Hilder W, et al.: Assessment of severity in colitis: a preliminary study. Gut 1975, 16:579\u2013584.","journal-title":"Gut"},{"key":"39_CR5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gut.38.6.905","volume":"38","author":"S Travis","year":"1996","unstructured":"Travis S, Farrant J, Ricketts C, et al.: Predicting outcome in severe ulcerative colitis. Gut 1996, 38:905\u2013910.","journal-title":"Gut"},{"key":"39_CR6","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1007\/BF02088063","volume":"39","author":"F Carbonnel","year":"1994","unstructured":"Carbonnel F, Lavergne A, Lemann A, et al.: Colonoscopy of acute colitis: a safe and reliable tool for assessment of severity. Dig Dis Sci 1994, 39:1550\u20131557.","journal-title":"Dig Dis Sci"},{"key":"39_CR7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/gut.45.5.693","volume":"45","author":"K Thiele","year":"1999","unstructured":"Thiele K, Bierhaus A, Autschbach F, et al.: Cell-specific effects of glucocorticoid treatment on the NK-kBp65\/ IkB system in patients with Crohn\u2019s disease. Gut 1999, 45:693\u2013704.","journal-title":"Gut"},{"key":"39_CR8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00054725-199503000-00006","volume":"1","author":"W Sandborn","year":"1995","unstructured":"Sandborn W: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995, 1:48\u201363. Reviews clinical efficacy of cyclosporine A in patients with severe ulcerative colitis, refractory Crohn\u2019s disease, or fistulizing Crohn\u2019s disease.","journal-title":"Inflamm Bowel Dis"},{"key":"39_CR9","first-page":"423","volume":"91","author":"W Sandborn","year":"1996","unstructured":"Sandborn W: A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996, 91:423\u2013433.","journal-title":"Am J Gastroenterol"},{"key":"39_CR10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11938-001-0032-4","volume":"4","author":"PE Legnani","year":"2001","unstructured":"Legnani PE, Kornbluth A: Immunomodulator therapy in inflammatory bowel disease. Curr Treat Opt Gastroenterol 2001, 4:199\u2013205.","journal-title":"Curr Treat Opt Gastroenterol"},{"key":"39_CR11","first-page":"383","volume-title":"Advanced Therapy of Inflammatory Bowel Disease","author":"B Feagan","year":"2000","unstructured":"Feagan B, Kumaranayake P: Methotrexate in inflammatory bowel disease. In Advanced Therapy of Inflammatory Bowel Disease. Edited by Bayless T, Hanauer S. Hamilton, Canada: BC Decker, Inc; 2000:383\u2013386."},{"key":"39_CR12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1572-0241.2000.02010.x","volume":"95","author":"T Orth","year":"2000","unstructured":"Orth T, Peters M, Schlaak J, et al.: Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000, 95:1201\u20131207.","journal-title":"Am J Gastroenterol"},{"key":"39_CR13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"S Targan","year":"1997","unstructured":"Targan S, Hanauer S, Deventer Sv, et al.: A short-term course study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn\u2019s disease. N Engl J Med 1997, 337:1029\u20131035.","journal-title":"N Engl J Med"},{"key":"39_CR14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","volume":"349","author":"W Stack","year":"1997","unstructured":"Stack W, Mann S, Roy A, et al.: Randomized controlled trial of CDP571 antibody to tumor necrosis factoralpha in Crohn\u2019s disease. Lancet 1997, 349:521\u2013524.","journal-title":"Lancet"},{"key":"39_CR15","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","volume":"177","author":"E Ehrenpreis","year":"1999","unstructured":"Ehrenpreis E, Kane S, Cohen L, et al.: Thalidomide therapy for patients with refractory Crohn\u2019s disease: an open-label trial. Gastroenterology 1999, 177:1271\u20131277.","journal-title":"Gastroenterology"},{"key":"39_CR16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","volume":"119","author":"E Vasiliauskas","year":"1999","unstructured":"Vasiliauskas E, Kam L, Abreu M, et al.: An open-label, stepwise dose-escalating pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn\u2019s disease. Gastroenterology 1999, 119:1278\u20131287.","journal-title":"Gastroenterology"},{"key":"39_CR17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/gut.40.4.470","volume":"40","author":"J Bauditz","year":"1997","unstructured":"Bauditz J, Haemling J, Ortner M, et al.: Treatment with tumor necrosis factor inhibitor oxypentifylline does not improve corticosteroid dependent chronic active Crohn\u2019s disease. Gut 1997, 40:470\u2013474.","journal-title":"Gut"},{"key":"39_CR18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0889-8553(05)70059-5","volume":"28","author":"B Sands","year":"1999","unstructured":"SandsB: Novel therapies for inflammatory bowel disease. Gastro Clin N Am 1999, 28:323\u2013351. Excellent review of emerging therapies for both ulcerative colitis and Crohn\u2019s disease with attention to biologic basis for potential efficacy of these medications as well as the results of published clinical trials.","journal-title":"Gastro Clin N Am"},{"key":"39_CR19","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1053\/gast.2000.20229","volume":"119","author":"R Fedorak","year":"2000","unstructured":"Fedorak R, Gangl A, Elson C, et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn\u2019s disease. Gastroenterology 2000, 119:1473\u20131482.","journal-title":"Gastroenterology"},{"key":"39_CR20","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/gast.2000.20196","volume":"119","author":"S Schreiber","year":"2000","unstructured":"Schreiber S, Fedorak R, Nielson O, et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn\u2019s disease. Gastroenterology 2000, 119:1461\u20131472.","journal-title":"Gastroenterology"},{"key":"39_CR21","first-page":"A927","volume":"112","author":"S Bank","year":"1997","unstructured":"Bank S, Sninsky C, Robinson M, et al.: Safety and activity evaluation of rhIL-11 in subjects with active Crohn\u2019s disease [abstract]. Gastroenterology 1997, 112:A927.","journal-title":"Gastroenterology"},{"key":"39_CR22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0016-5085(99)70550-0","volume":"117","author":"B Sands","year":"1999","unstructured":"Sands B, Banks S, Sninsky C, et al.: Preliminary evaluation of safety and activity of recombinant human interleukin-11 in patients with active Crohn\u2019s disease. Gastroenterology 1999, 117:58\u201364.","journal-title":"Gastroenterology"},{"key":"39_CR23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJM199403243301202","volume":"330","author":"R Pullan","year":"1994","unstructured":"Pullan R, Rhodes J, Ganesh S, et al.: Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994, 330:811\u2013815.","journal-title":"N Engl J Med"},{"key":"39_CR24","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM200006013422203","volume":"342","author":"AE Slonim","year":"2000","unstructured":"Slonim AE, Bulone L, Damore MB, et al.: A preliminary study of growth hormone therapy for Crohn\u2019s disease. N Engl J Med 2000, 342:1633\u20131637.","journal-title":"N Engl J Med"},{"key":"39_CR25","first-page":"A3034","volume":"118","author":"J Lewis","year":"2000","unstructured":"Lewis J, Lichtenstein GR, Stein R, Deren J, et al.: Treatment of ulcerative colitis with PPAR-gamma ligands: preliminary results of a pilot study [abstact]. Gastroenterology 2000, 118:A3034.","journal-title":"Gastroenterology"},{"key":"39_CR26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11938-001-0033-3","volume":"4","author":"M O\u2019Sullivan","year":"2001","unstructured":"O\u2019Sullivan M, O\u2019Morain C: Nutritional treatments in inflammatory bowel disease. Curr Treat Opt Gastroenterol 2001, 4:207\u2013213.","journal-title":"Curr Treat Opt Gastroenterol"},{"key":"39_CR27","unstructured":"VISN4 Formulary. Valley Forge, PA: AmeriSource Health Corporation; 2001."}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-001-0039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-001-0039-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-001-0039-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:56:55Z","timestamp":1559422615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-001-0039-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1007\/s11938-001-0039-x","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}